achieve life sciences - ACHV
ACHV
Close Chg Chg %
3.07 0.02 0.65%
Open Market
3.09
+0.02 (0.65%)
Volume: 379.92K
Last Updated:
Jan 17, 2025, 4:00 PM EDT
Company Overview: achieve life sciences - ACHV
ACHV Key Data
Open $3.09 | Day Range 3.02 - 3.14 |
52 Week Range 3.02 - 5.59 | Market Cap $105.58M |
Shares Outstanding 34.39M | Public Float 27.60M |
Beta 1.67 | Rev. Per Employee N/A |
P/E Ratio N/A | EPS -$1.13 |
Yield 0.00% | Dividend N/A |
EX-DIVIDEND DATE | SHORT INTEREST N/A |
AVERAGE VOLUME 277.43K |
ACHV Performance
1 Week | 0.00% | ||
1 Month | -16.26% | ||
3 Months | -39.17% | ||
1 Year | -31.64% | ||
5 Years | -75.78% |
ACHV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About achieve life sciences - ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
ACHV At a Glance
Achieve Life Sciences, Inc.
1040 West Georgia Street
Vancouver, British Columbia V6E 4H1
Phone | 1-604-210-2217 | Revenue | 0.00 | |
Industry | Pharmaceuticals: Major | Net Income | -29,815,000.00 | |
Sector | Health Technology | Employees | 22 | |
Fiscal Year-end | 12 / 2024 | |||
View SEC Filings |
ACHV Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | N/A |
Price to Book Ratio | N/A |
Price to Cash Flow Ratio | N/A |
Enterprise Value to EBITDA | -3.067 |
Enterprise Value to Sales | N/A |
Total Debt to Enterprise Value | 0.202 |
ACHV Efficiency
Revenue/Employee | N/A |
Income Per Employee | -1,355,227.273 |
Receivables Turnover | N/A |
Total Asset Turnover | N/A |
ACHV Liquidity
Current Ratio | 0.816 |
Quick Ratio | 0.816 |
Cash Ratio | 0.747 |
ACHV Profitability
Gross Margin | N/A |
Operating Margin | N/A |
Pretax Margin | N/A |
Net Margin | N/A |
Return on Assets | -120.85 |
Return on Equity | -869.876 |
Return on Total Capital | -195.086 |
Return on Invested Capital | -860.462 |
ACHV Capital Structure
Total Debt to Total Equity | N/A |
Total Debt to Total Capital | 109.475 |
Total Debt to Total Assets | 86.371 |
Long-Term Debt to Equity | N/A |
Long-Term Debt to Total Capital | 0.039 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Achieve Life Sciences - ACHV
Collapse All in section
All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 255.00K | 250.00K | 236.00K | 228.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 255.00K | 250.00K | 236.00K | 228.00K | |
Depreciation
| 32.00K | 27.00K | 36.00K | 28.00K | |
Amortization of Intangibles
| 223.00K | 223.00K | 200.00K | 200.00K | |
COGS Growth
| +0.39% | -1.96% | -5.60% | -3.39% | |
Gross Income
| (255.00K) | (250.00K) | (236.00K) | (228.00K) | |
Gross Income Growth
| -0.39% | +1.96% | +5.60% | +3.39% | |
Gross Profit Margin
| - | - | - | - | - |
2020 | 2021 | 2022 | 2023 | 5-year trend | |
---|---|---|---|---|---|
SG&A Expense
| 14.49M | 32.84M | 40.56M | 27.02M | |
Research & Development
| 6.88M | 23.97M | 30.08M | 15.81M | |
Other SG&A
| 7.61M | 8.88M | 10.49M | 11.21M | |
SGA Growth
| -10.93% | +126.59% | +23.51% | -33.38% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 528.00K | - |
EBIT after Unusual Expense
| (14.75M) | (33.09M) | (40.80M) | (27.78M) | |
Non Operating Income/Expense
| 20.00K | (58.00K) | 239.00K | 816.00K | |
Non-Operating Interest Income
| 69.00K | 17.00K | 199.00K | 825.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 1.79M | 2.85M | - |
Interest Expense Growth
| - | - | - | +59.47% | - |
Gross Interest Expense
| - | - | 1.79M | 2.85M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (14.73M) | (33.15M) | (42.35M) | (29.82M) | |
Pretax Income Growth
| +10.16% | -125.06% | -27.74% | +29.60% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (14.73M) | (33.15M) | (42.35M) | (29.82M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (14.73M) | (33.15M) | (42.35M) | (29.82M) | |
Net Income Growth
| +10.16% | -125.06% | -27.74% | +29.60% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (14.73M) | (33.15M) | (42.35M) | (29.82M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (14.73M) | (33.15M) | (42.35M) | (29.82M) | |
EPS (Basic)
| -5.4176 | -4.0828 | -3.9979 | -1.5037 | |
EPS (Basic) Growth
| +86.38% | +24.64% | +2.08% | +62.39% | |
Basic Shares Outstanding
| 2.72M | 8.12M | 10.59M | 19.83M | |
EPS (Diluted)
| -5.4176 | -4.0828 | -3.9979 | -1.5037 | |
EPS (Diluted) Growth
| +86.38% | +24.64% | +2.08% | +62.39% | |
Diluted Shares Outstanding
| 2.72M | 8.12M | 10.59M | 19.83M | |
EBITDA
| (14.49M) | (32.84M) | (40.56M) | (27.02M) | |
EBITDA Growth
| +10.93% | -126.59% | -23.51% | +33.38% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
Average Recommendation | BUY | Average Target Price | 16.00 | |
Number of Ratings | 8 | Current Quarters Estimate | -0.355 | |
FY Report Date | 03 / 2025 | Current Year's Estimate | -1.144 | |
Last Quarter’s Earnings | -0.36 | Median PE on CY Estimate | N/A | |
Year Ago Earnings | -1.221 | Next Fiscal Year Estimate | -0.608 | |
Median PE on Next FY Estimate | N/A |
Earnings Per Share
This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
---|---|---|---|---|
# of Estimates | 4 | 4 | 8 | 5 |
Mean Estimate | -0.36 | -0.30 | -1.14 | -0.61 |
High Estimates | -0.31 | -0.23 | -0.86 | 0.08 |
Low Estimate | -0.42 | -0.36 | -1.41 | -1.04 |
Coefficient of Variance | -14.27 | -18.08 | -17.41 | -84.28 |
Analysts Recommendations
Current | 1 Month Ago | 3 Months Ago | |
---|---|---|---|
BUY | 8 | 8 | 7 |
OVERWEIGHT | 0 | 0 | 0 |
HOLD | 0 | 0 | 0 |
UNDERWEIGHT | 0 | 0 | 0 |
SELL | 0 | 0 | 0 |
MEAN | Buy | Buy | Buy |
SEC Filings for Achieve Life Sciences - ACHV
Filing Date | Type | Category | Amended |
---|---|---|---|
No results |
Insider Actions for Achieve Life Sciences - ACHV
Date | Name | Shares | Transaction | Value |
---|---|---|---|---|
Apr 24, 2024 | Cindy A. Jacobs President & CMO; Director | 34,511 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | Cindy A. Jacobs President & CMO; Director | 30,554 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share | 137,798.54 |
Apr 24, 2024 | Cindy A. Jacobs President & CMO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | John A. Bencich CEO; Director | 101,724 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | John A. Bencich CEO; Director | 95,636 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share | 431,318.36 |
Apr 24, 2024 | John A. Bencich CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | Richard Alistair Balfour Stewart Executive Chairman; Director | 61,001 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | Richard Alistair Balfour Stewart Executive Chairman; Director | 50,876 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share | 229,450.76 |
Apr 24, 2024 | Richard Alistair Balfour Stewart Executive Chairman; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | Jerry Wan Principal Accounting Officer | 12,057 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Apr 24, 2024 | Jerry Wan Principal Accounting Officer | 9,807 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share | 44,229.57 |
Apr 24, 2024 | Jerry Wan Principal Accounting Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Jan 30, 2024 | Bridget A. Martell Director | 31,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |